442 related articles for article (PubMed ID: 15155143)
1. Emerging oral drugs for erectile dysfunction.
Briganti A; Salonia A; Gallina A; Suardi N; Rigatti P; Montorsi F
Expert Opin Emerg Drugs; 2004 May; 9(1):179-89. PubMed ID: 15155143
[TBL] [Abstract][Full Text] [Related]
2. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Gallina A; Saccà A; Montorsi P; Rigatti P; Montorsi F
Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological management of erectile dysfunction.
Montorsi F; Salonia A; Deho' F; Cestari A; Guazzoni G; Rigatti P; Stief C
BJU Int; 2003 Mar; 91(5):446-54. PubMed ID: 12603396
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
Ali ST
Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Vickers MA; Satyanarayana R
Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
[TBL] [Abstract][Full Text] [Related]
6. Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysis.
Hatzichristou DG; Aliotta P; Auerbach S; Barkin J; Lording D; Murdock M; Wilkins HJ; McBride TA; Colopy MW; Carson CC;
Clin Ther; 2005 Sep; 27(9):1452-61. PubMed ID: 16291418
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunction.
Lammers PI; Rubio-Aurioles E; Castell R; Castaneda J; Ponce de Leon R; Hurley D; Lipezker M; Loehr LA; Lowrey F
Int J Impot Res; 2002 Feb; 14(1):54-9; discussion 60. PubMed ID: 11896479
[TBL] [Abstract][Full Text] [Related]
8. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
Hatzimouratidis K; Hatzichristou DG
Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698
[TBL] [Abstract][Full Text] [Related]
9. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
10. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
Rosen RC; McKenna KE
Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729
[TBL] [Abstract][Full Text] [Related]
11. Sublingual apomorphine: new preparation. In erectile disorders: a narrow therapeutic margin.
Prescrire Int; 2002 Jun; 11(59):76-9. PubMed ID: 12068841
[TBL] [Abstract][Full Text] [Related]
12. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
[TBL] [Abstract][Full Text] [Related]
13. Treatment of erectile dysfunction.
Dinsmore W
Int J STD AIDS; 2004 Apr; 15(4):215-21. PubMed ID: 15075013
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
15. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Doggrell S
Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
[TBL] [Abstract][Full Text] [Related]
16. Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial.
Carson CC; Hatzichristou DG; Carrier S; Lording D; Lyngdorf P; Aliotta P; Auerbach S; Murdock M; Wilkins HJ; McBride TA; Colopy MW;
BJU Int; 2004 Dec; 94(9):1301-9. PubMed ID: 15610110
[TBL] [Abstract][Full Text] [Related]
17. [New treatment options for erectile dysfunction. Pharmacologic and nonpharmacologic options].
Sperling H; Lümmen G; Schneider T; Rübben H
Herz; 2003 Jun; 28(4):314-24. PubMed ID: 12825147
[TBL] [Abstract][Full Text] [Related]
18. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
Ströberg P; Hedelin H; Ljunggren C
Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
[TBL] [Abstract][Full Text] [Related]
19. [Erectile dysfunction].
Isidori A; Aversa A; Fabbri A
Recenti Prog Med; 1999; 90(7-8):396-402. PubMed ID: 10429521
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
